Company Overview and News

Carnarvon Petroleum set to "bring forward the next phases of value for shareholders"

Carnarvon Petroleum Ltd (ASX:CVN) managing director Adrian Cook speaks to Proactive Investors, as drilling happens at Western Australia's prolific North West Shelf.

Carnarvon Petroleum about to set-up Dorado-1 well targeting gas and liquids

Carnarvon Petroleum Limited (ASX:CVN) is about to start drilling set-up for the Dorado-1 well which will target gas and liquids at the Phoenix project on the North West Shelf.

Carnarvon Petroleum’s Phoenix South-3 well reaches 3,733 metres targeting North West Shelf gas and liquids

Carnarvon Petroleum Limited (ASX:CVN) advises that drilling of the Phoenix South-3 well has reached 3,733 metres measured depth on its way down to gas and condensate in the Caley Member at about 5,300 metres.

Carnarvon in $20m raising

Carnarvon Petroleum has boosted its coffers with a $16 million capital raising to fund drilling at its Buffalo oil field in the North West Shelf, while also announcing a share purchase plan to raise up to $4 million.

Carnarvon Petroleum on schedule with drilling at Phoenix South-3 well

Carnarvon Petroleum Limited (ASX:CVN) is progressing as planned at the Phoenix South-3 well aimed at evaluating the gas and condensate potential of the Caley Member at the Phoenix project on the North West Shelf.

Carnarvon Petroleum raises $16 million to assist in redeveloping the Buffalo oil field

Carnarvon Petroleum Limited (ASX:CVN) has raised $16 million in a placement to facilitate redevelopment of the Buffalo oil field on the North West Shelf.

Carnarvon Petroleum enters trading halt ahead of capital raising

Carnarvon Petroleum Ltd (ASX:CVN) has been granted a trading halt by the ASX pending the release of information regarding a proposed capital raising.

Carnarvon Petroleum moves closer to oil production at Buffalo with preparations for first well

Carnarvon Petroleum Limited (ASX:CVN) is progressing redevelopment plans for the Buffalo Oil Field in the Timor Sea with preparations being made to drill the first production well.

Carnarvon Petroleum expects to start drilling for gas and liquids at Dorado-1 by end of May

Carnarvon Petroleum Limited (ASX:CVN) and Quadrant Energy expect to start drilling the Dorado-1 well targeting gas and liquids on the North West Shelf by the end of May.

Carnarvon Petroleum on track with Phoenix South-3 drilling program

Carnarvon Petroleum Limited (ASX:CVN) has provided an update on the drilling of the Phoenix South-3 well, offshore Western Australia.

Carnarvon Petroleum drilling to add to gas and condensate bounty at Phoenix project

Carnarvon Petroleum Limited (ASX:CVN) aims to add more than 1 trillion standard cubic feet of gas and 88 million barrels of associated condensate from drilling underway on the North West Shelf of Western Australia.

Carnarvon Petroleum begins drilling Phoenix South-3 well to unlock gas, condensate potential

Carnarvon Petroleum Limited (ASX:CVN) and its joint venture partner and project operator Quadrant Energy have commenced drilling at the Phoenix South-3 well.

Carnarvon Petroleum trades strongly ahead of active drilling campaign

Carnarvon Petroleum Limited (ASX:CVN) and its joint venture partner Quadrant Energy are preparing to commence drilling at the Phoenix South-3 well.

Carnarvon Petroleum expects drilling to start shortly at Phoenix South-3 after rig arrives

Carnarvon Petroleum Limited (ASX:CVN) expects drilling will start at the Phoenix South-3 well on Western Australia's North West Shelf shortly with the rig now at the site.

Carnarvon Petroleum rig delay only a small hitch ahead of a big year of exploration

Carnarvon Petroleum Limited (ASX:CVN) expects to start drilling the Phoenix South-3 well on Western Australia's North West Shelf around April 10.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...